BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32046452)

  • 1. Does Adding Fluoxetine to Combined Oral Contraceptives Containing Drospirenone Improve the Management of Severe Premenstrual Syndrome? A 6-Month Randomized Double-Blind Placebo-Controlled Three-Arm Trial.
    Shehata NAA; Moety GAFA; El Wahed HAA; Fahim AS; Katta MA; Hussein GK
    Reprod Sci; 2020 Feb; 27(2):743-750. PubMed ID: 32046452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral contraceptives containing drospirenone for premenstrual syndrome.
    Lopez LM; Kaptein AA; Helmerhorst FM
    Cochrane Database Syst Rev; 2012 Feb; (2):CD006586. PubMed ID: 22336820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral contraceptives containing drospirenone for premenstrual syndrome.
    Lopez LM; Kaptein AA; Helmerhorst FM
    Cochrane Database Syst Rev; 2009 Apr; (2):CD006586. PubMed ID: 19370644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral contraceptives containing drospirenone for premenstrual syndrome.
    Lopez LM; Kaptein A; Helmerhorst FM
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006586. PubMed ID: 18254106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The efficiency of oral contraception containing drospirenone in treating symptoms of premenstrual syndrome or premenstrual dysphoric disorder in gyneacology practice].
    Svojanovská K
    Ceska Gynekol; 2010 Oct; 75(5):474-80. PubMed ID: 21374928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral contraceptives containing drospirenone for premenstrual syndrome.
    Ma S; Song SJ
    Cochrane Database Syst Rev; 2023 Jun; 6(6):CD006586. PubMed ID: 37365881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Premenstrual Breakthrough of Depression With Adjunctive Oral Contraceptive Pills Compared With Placebo.
    Peters W; Freeman MP; Kim S; Cohen LS; Joffe H
    J Clin Psychopharmacol; 2017 Oct; 37(5):609-614. PubMed ID: 28816924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder.
    Freeman EW; Kroll R; Rapkin A; Pearlstein T; Brown C; Parsey K; Zhang P; Patel H; Foegh M;
    J Womens Health Gend Based Med; 2001; 10(6):561-9. PubMed ID: 11559453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RETRACTED: Calcium versus oral contraceptive pills containing drospirenone for the treatment of mild to moderate premenstrual syndrome: a double blind randomized placebo controlled trial.
    Shehata NAA
    Eur J Obstet Gynecol Reprod Biol; 2016 Mar; 198():100-104. PubMed ID: 26808666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in the treatment of premenstrual dysphoric disorder: a randomized, double blind placebo-controlled study].
    Fu Y; Mi W; Li L; Zhang H; Wang J; Cheng W; Sun L; Li L; Xie S; Zhang J
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):506-9. PubMed ID: 25327732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.
    Yonkers KA; Brown C; Pearlstein TB; Foegh M; Sampson-Landers C; Rapkin A
    Obstet Gynecol; 2005 Sep; 106(3):492-501. PubMed ID: 16135578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder.
    Freeman EW
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():27-34; discussion 42-3. PubMed ID: 12659404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive.
    Graham CA; Sherwin BB
    J Psychosom Res; 1992 Apr; 36(3):257-66. PubMed ID: 1564678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low doses of fluoxetine for the treatment of emotional premenstrual syndrome: a randomized double-blind, placebo-controlled, pilot study.
    Maranho MCMF; Guapo VG; de Rezende MG; Vieira CS; Brandão ML; Graeff FG; Lovick T; Del-Ben CM
    Psychoneuroendocrinology; 2023 Nov; 157():106360. PubMed ID: 37572412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoxetine in the treatment of premenstrual syndrome.
    Stone AB; Pearlstein TB; Brown WA
    Psychopharmacol Bull; 1990; 26(3):331-5. PubMed ID: 2274633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethinyl estradiol 20μg/drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder.
    Marr J; Heinemann K; Kunz M; Rapkin A
    Int J Gynaecol Obstet; 2011 May; 113(2):103-7. PubMed ID: 21338987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
    Pearlstein TB; Bachmann GA; Zacur HA; Yonkers KA
    Contraception; 2005 Dec; 72(6):414-21. PubMed ID: 16307962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A lecithin phosphatidylserine and phosphatidic acid complex (PAS) reduces symptoms of the premenstrual syndrome (PMS): Results of a randomized, placebo-controlled, double-blind clinical trial.
    Schmidt K; Weber N; Steiner M; Meyer N; Dubberke A; Rutenberg D; Hellhammer J
    Clin Nutr ESPEN; 2018 Apr; 24():22-30. PubMed ID: 29576358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment.
    Lucky AW; Koltun W; Thiboutot D; Niknian M; Sampson-Landers C; Korner P; Marr J
    Cutis; 2008 Aug; 82(2):143-50. PubMed ID: 18792547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
    Marr J; Gerlinger C; Kunz M
    Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.